Journal
CANCER CHEMOTHERAPY AND PHARMACOLOGY
Volume 73, Issue 1, Pages 131-137Publisher
SPRINGER
DOI: 10.1007/s00280-013-2329-0
Keywords
NSCLC; Chemotherapy; Biomarker; EGFR; Heterogeneity
Categories
Funding
- Danish Cancer Research Foundation
- Arvid Nillsons Foundation
- Torben and Alice Frimodts Foundation
- Aase and Ejnar Danielsens Foundation
- Eva and Henry Fraenkels Foundation
- Danish Research Foundation
- Snedkermester Sophus Jacobsen and Hustru Astrid Jacobsens Foundation
- Foundation for the Promotion of Medical Cancer Treatment
- Research Foundation of the Department of Oncology, Rigshospitalet
Ask authors/readers for more resources
Antibodies targeting epidermal growth factor receptor (EGFR), such as cetuximab, may potentially improve outcome in non-small cell lung cancer (NSCLC) patients with high EGFR expression. The EGFR expression may be heterogeneously distributed within tumors, and small biopsies may thus not accurately reveal the EGFR expression. In addition, EGFR expression may also change during chemotherapy. The current study investigates the magnitude of these two issues. EGFR expression in diagnostic biopsies and resection specimen was compared in 53 NSCLC patients stage T1-4N0-1M0 treated with surgery without preceding chemotherapy (OP group), and 65 NSCLC patients stage T1-3N0-2M0 (NAC group) treated with preoperative carboplatin and paclitaxel in order to evaluate the discordance of EGFR expression between samples. Discordance between tumors dichotomized according to EGFR expression (high: H-score a parts per thousand yen200; low: H-score < 200) in diagnostic biopsies and immediate resection specimens was 25 % in the OP group and 33 % in the NAC group (p = 0.628). Five (9 %) of primary tumors in the OP group and 4 (13 %) in the NAC group had increased EGFR expression in the resection specimens as compared to the diagnostic biopsies (p = 0.583). A decrease in EGFR expression was observed in 6 (11 %) in the OP group and 7 (23 %) in the NAC group (p = 0.148). EGFR expression in 25 % of diagnostic biopsies may potentially not be accurate compared to the prevailing pattern in the whole tumor based on the larger resection specimens. This may potentially be an obstacle for proper use of antibodies targeting the EGFR in NSCLC. EGFR expression does, however, not change significantly during paclitaxel and carboplatin and rebiopsies in order to decide on anti-EGFR antibody therapy following chemotherapy do not seem warranted.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available